2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
This guideline cites 7 of the 199 landmark trials in our Cardiology register.
- Issued by
- ESC
- Year
- 2022
- Source
- Zeppenfeld K, Tfelt-Hansen J, et al. Eur Heart J. 2022;43(40):3997–4126.doi 10.1093/eurheartj/ehac262
The 2022 ESC guideline covers risk stratification, the ICD for primary and secondary prevention of sudden cardiac death, catheter ablation of ventricular tachycardia, and disease-specific pathways. Below are the register's landmark device trials that underpin its ICD and CRT recommendations.
Primary-prevention ICD3
- 2016DANISHCardiology · Arrhythmia · ICDIn 1,116 patients with non-ischaemic heart failure (EF ≤ 35 %), a prophylactic defibrillator did not reduce all-cause mortality compared with usual care.HR 0.87Read →
- 2005SCD-HeFT CoreCardiology · Arrhythmia · ICDIn 2,521 patients with heart failure (NYHA II–III, EF ≤ 35 %), an implantable defibrillator reduced all-cause mortality compared with placebo or amiodarone.Read →
- 2002MADIT-II CoreCardiology · Arrhythmia · ICDIn 1,232 patients with prior MI and an ejection fraction ≤ 30 %, a prophylactic implantable defibrillator reduced all-cause mortality compared with conventional therapy.HR 0.69Read →
Subcutaneous vs. transvenous ICD1
- 2020PRAETORIANCardiology · Arrhythmia · ICDIn 849 patients needing a defibrillator but no pacing, a subcutaneous ICD was non-inferior to a transvenous ICD for device complications and inappropriate shocks.HR 0.9995% CI 0.71-1.39Read →
Cardiac resynchronisation therapy3
- 2009MADIT-CRTCardiology · Arrhythmia · CRTIn 1,820 patients with mild heart failure (NYHA I–II) and a wide QRS, adding resynchronisation to a defibrillator reduced death or heart-failure events compared with a defibrillator alone.HR 0.66Read →
- 2005CARE-HF CoreCardiology · Arrhythmia · CRTIn 813 patients with heart failure and a wide QRS, cardiac resynchronisation therapy reduced death or unplanned cardiovascular hospitalisation compared with medical therapy.39% vs 55%Read →
- 2004COMPANIONCardiology · Arrhythmia · CRTIn 1,520 patients with NYHA III-IV heart failure and QRS ≥ 120 ms, cardiac resynchronisation therapy (with or without a defibrillator) reduced all-cause death or hospitalisation compared with optimal medical therapy alone.Read →
Cited landmark trials not yet in the register4
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.